Oral News and Research

RSS

Fluoride in drinking water and oral-care products prevents tooth decay, shows research

In an advance toward solving a 50-year-old mystery, scientists are reporting new evidence on how the fluoride in drinking water, toothpastes, mouth rinses and other oral-care products prevents tooth decay.

2 May 2013

Prosigna Breast Cancer Prognostic Gene Signature Assay predicts ROR in women with early-stage breast cancer

NanoString Technologies, Inc., a privately held provider of life science tools for translational research and molecular diagnostic products, today announced results from two studies that are featured in oral presentations this week at IMPAKT Breast Cancer Conference.

2 May 2013

AcelRx Pharmaceuticals reports clinical results of Sufentanil NanoTab PCA System for acute pain treatment

AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today reported additional clinical results for its lead product candidate, the Sufentanil NanoTab PCA System for the treatment of moderate-to-severe acute pain in the hospital setting.

2 May 2013

Specific inflammatory pattern found in patients with pneumonia and COPD

Patients with community-acquired pneumonia on a background of chronic obstructive pulmonary disease have a different early inflammatory pattern than patients with CAP only, a prospective study shows.

30 Apr 2013

Experts call for medical leaders to establish guidelines, embed honesty in academic cultures

Unethical behavior among physicians-in-training threatens to erode public trust and confidence in the medical profession, say two academic physicians in the current issue of Mayo Clinic Proceedings.

30 Apr 2013

Clinical trial to treat Female Orgasmic Disorder

Columbia University School of Nursing is the only site in New York State, and one of only 30 international sites selected to participate in a clinical trial to treat Acquired Female Orgasmic Disorder.

30 Apr 2013

FDA approves Octapharma USA's BLA for octaplex

The U.S. Food and Drug Administration has accepted Octapharma USA's Biological License Application for octaplex.

30 Apr 2013

Merck, Pfizer sign collaboration agreement for development and commercialization of ertugliflozin

Merck & Co., Inc., known as MSD outside the United States and Canada, and Pfizer Inc. today announced that they have entered into a worldwide (except Japan) collaboration agreement for the development and commercialization of Pfizer's ertugliflozin (PF-04971729), an investigational oral sodium glucose cotransporter (SGLT2) inhibitor being evaluated for the treatment of type 2 diabetes.

From Pfizer, Inc. 30 Apr 2013

Dental problems create substantial burden

Over 40 million hours are lost each year due to dental problems and their treatment in the Canadian population, study findings indicate.

29 Apr 2013

Specific inflammatory pattern found in patients with pneumonia and COPD

Patients with community-acquired pneumonia on a background of chronic obstructive pulmonary disease have a different early inflammatory pattern than patients with CAP only, a prospective study shows.

29 Apr 2013

Osteomyelitis guidelines push pediatric care

US clinicians have demonstrated the benefits of multidisciplinary evidence-based guidelines for the treatment of children with osteomyelitis.

29 Apr 2013

Maruishi gains exclusive rights to develop, commercialize Cara Therapeutics' CR845 in Japan

Cara Therapeutics, Inc. and Maruishi Pharmaceutical Company, Ltd. today announced that they have entered into a License Agreement providing Maruishi with exclusive rights to develop, manufacture and commercialize Cara's lead analgesic drug candidate, CR845, for acute pain and uremic pruritus in Japan.

29 Apr 2013

Oramed to report results of T1DM oral insulin formulation at Diabetes Summit 2013

Oramed Pharmaceuticals Inc., a developer of oral delivery systems of drugs currently administered by injection, announced today that its abstract, entitled "Oral insulin capsules toward management of Type 1 diabetes mellitus," will be presented at the Global Technology Community Diabetes Summit 2013.

29 Apr 2013

Transgene announces pre-clinical data of TG1050 for treatment of chronic hepatitis B infection

Transgene SA, a biopharmaceutical company that develops targeted immunotherapy products to treat major unmet medical needs in cancer and chronic infectious diseases, announced pre-clinical data obtained with its novel immunotherapeutic, TG1050, to treat chronic hepatitis B infection.

29 Apr 2013

Cempra demonstrates solithromycin's potential against urogenital infections at ECCMID

Cempra, Inc., a clinical-stage pharmaceutical company focused on developing differentiated antibiotics to meet critical medical needs in the treatment of bacterial infections, today announced that it will present data at the European Congress of Clinical Microbiology and Infectious Diseases in Berlin, demonstrating solithromycin's potential to treat urogenital infections and combat challenging pathogens such as enterococci and Legionella pneumophila.

29 Apr 2013

Practical guidelines on the use of new oral anticoagulants

A practical guide on the use of the new oral anticoagulants has been produced by the European Heart Rhythm Association of the European Society of Cardiology.

29 Apr 2013

Metabolic risk factors in overweight children linked with mild artery wall stiffness

Metabolic disorders, such as excess abdominal fat, raised blood pressure, higher levels of insulin, glucose and triglycerides and lower levels of the beneficial HDL cholesterol can be found in children as young as 6 to 8 years of age, according to a study carried out at the University of Eastern Finland.

26 Apr 2013

Cempra reports net loss of $10.3 million in first quarter 2013

Cempra, Inc., a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the treatment of bacterial infectious diseases, today reported financial results for the first quarter ended March 31, 2013.

26 Apr 2013

Studies demonstrate encouraging results for new direct-acting antiviral agents

New data from a number of clinical trials presented for the first time at the International Liver Congress- 2013 demonstrate encouraging results in the use of new direct-acting antiviral agents (DAAs) for the treatment of hepatitis C.

25 Apr 2013

Perosphere, Daiichi Sankyo sign clinical trial agreement

Perosphere Inc. and Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) announced today that they have entered into a clinical trial agreement under which Daiichi Sankyo will support and co-sponsor a phase 1 clinical study testing the safety, tolerability and effectiveness of PER977 to reverse the anticoagulant activity of edoxaban, Daiichi Sankyo's investigational oral, once-daily, direct factor Xa-inhibitor.

25 Apr 2013

Oral News and Research

Fluoride in drinking water and oral-care products prevents tooth decay, shows research

Prosigna Breast Cancer Prognostic Gene Signature Assay predicts ROR in women with early-stage breast cancer

AcelRx Pharmaceuticals reports clinical results of Sufentanil NanoTab PCA System for acute pain treatment

Specific inflammatory pattern found in patients with pneumonia and COPD

Experts call for medical leaders to establish guidelines, embed honesty in academic cultures

Clinical trial to treat Female Orgasmic Disorder

FDA approves Octapharma USA's BLA for octaplex

Merck, Pfizer sign collaboration agreement for development and commercialization of ertugliflozin

Dental problems create substantial burden

Specific inflammatory pattern found in patients with pneumonia and COPD

Osteomyelitis guidelines push pediatric care

Maruishi gains exclusive rights to develop, commercialize Cara Therapeutics' CR845 in Japan

Oramed to report results of T1DM oral insulin formulation at Diabetes Summit 2013

Transgene announces pre-clinical data of TG1050 for treatment of chronic hepatitis B infection

Cempra demonstrates solithromycin's potential against urogenital infections at ECCMID

Practical guidelines on the use of new oral anticoagulants

Metabolic risk factors in overweight children linked with mild artery wall stiffness

Cempra reports net loss of $10.3 million in first quarter 2013

Studies demonstrate encouraging results for new direct-acting antiviral agents

Perosphere, Daiichi Sankyo sign clinical trial agreement

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

Latest News